Methylene Blue Intravenously and Chronic Neuropathic Pain
NCT ID: NCT02303886
Last Updated: 2014-12-01
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
10 participants
INTERVENTIONAL
2009-03-31
2014-11-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Methods Ten patients with neuropathic pain were randomized to receive one of the two treatments: methylene blue (MB1) 2 mg/kg (10 mg/mL Methyltioninklorid, Apoteket, Umeå, Sweden) or methylene blue (MB2) 0.02 mg/kg. Both MB solutions were infused intravenously over 60 minutes. The sensory function and the pain were evaluated at baseline and at 60 min after the start of infusions. A pain journal was kept by the patients in the following 5 days. Plasma and urinary concentrations of 8-isoprostane-prostaglandin F2α (8-iso-PGF2α) an indicator of oxidative injury, were measured with radioimmunoassay (RIA). A panel of 92 proteins biomarkers were determined with Proximity Extension Assay (PEA) prior and after infusions.
comparison with the control group. MB infusion produced an enhancement of prolactin.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Administration of study drug Ten patients were randomized by a computer generated random list to receive either methylene blue 2mg/kg (10 mg/mL Methyltioninklorid, Apoteket, Umeå, Sweden) or methylene blue 0.02 mg/kg (that served as control), both infused intravenously over 60 minutes. After monitors for electrocardiography, noninvasive arterial blood pressure, and pulse oximetry were attached, a dedicated 20-gauge cannula was inserted into the dorsum of the nondominant hand for administration of the study drugs. The pain was measured at baseline and at 60 min after the start of infusion (NRS scale) and also with a pain diary during the next 24 hours and the following 5 days. ECG, pulse, blood pressure, O2 saturation, were continuously recorded during the infusion. Blood and urine samples were taken before and after the infusion of MB. Neither the subjects of the experiment nor the person examining the patients knew the concentration of MB in the infusion. The infusions of methylene blue in sterile saline (NaCl 0.9%) were prepared by another person who had access to the randomization list but not involved in the monitoring of the patients. The infusions bags were covered in opaque red wrappes and the infusions sets were opaque.
Pain Assessment were performed Before and after MB administration, Evaluation of sensory function was performed using bedside examination according to EFNS guidelines: light touch, pinprick sense, warmth (40°) and cold (25°) temperature stimuli were tested. The contralateral uninjured side served as within-patient control. The patient compared the sensations in both between sides and reported if there was any hypoesthesia, hyperesthesia, allodynia or simply normal sensations to the different stimuli. The pain recordings were determined before and after infusion of MB. Patients kept a diary where they could pick their pain levels on a scale between 0 and 10 (NRS) at every 6 hours after the infusion in the first 24 hours and at 8 hours in the next 5 days.
Peripheral venous blood was drawn from fasting subjects using a 19-gauge needle. Urine was collected into additive-free tubes. Plasma was prepared from blood collected into tubes containing heparin by centrifugation (3500x g for 12 min). Urine and plasma samples were stored at -70◦C until analysis. Blood and urine samples were collected before and after the infusion of MB.
Plasma and urine concentrations of isoprostane 8-iso-PGF2 alpha (an indicator of oxidative injury),Proximity Extension Assay (PEA) has been found to have specificity of detection and analysis of an increased range of target molecules. PEA technology involved in this study a panel of 92 oligonucleotide labeled antibody probe pairs (Proseek assay kit), Non-parametric statistical methods were performed by the author with GraphPad PRISM 5.0 (GraphPad Software, La Jolla, San Diego, CA, www.graphpad.com 5.0). Data are presented as mean and SD with 95% confidence intervals. The level of significance was set at a p value \<.05.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
CROSSOVER
TREATMENT
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
A Methylene blue 10 mg/ml 2mg/kg
ten patients that recieved MB1 methylene blue 2 mg/kg infusion under 60 min
Methylene blue
In NaCL0.9% 100 ml
Methylene blue
in NaCl 0.9% 100 ml
B Methylene blue 10 mg/ml 0.02 mg/kg
Same patients received MB2 Methylene blue 0.02 mg/kg infusion under 60 min
Methylene blue
In NaCL0.9% 100 ml
Methylene blue
in NaCl 0.9% 100 ml
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Methylene blue
In NaCL0.9% 100 ml
Methylene blue
in NaCl 0.9% 100 ml
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Be able to understand and comply with the requirements of the study
* Patients with a history of persistent peripheral and central neuropathic pain interfering with daily activities of at least 3 months duration
* Patients with previous unsuccessful treatment of neuropathic pain
* Spontaneous or evoked pain upon standardized test (mechanical, movement)\> 50 on a 100 mm VAS scale
* Informed written consent
Exclusion Criteria
* Any condition/disease that could interfere with the study measurements, e.g. peripheral vascular disease, diabetes mellitus, alcohol/opioids addiction
* Noncooperation, insufficient Swedish language
* Treatment with antidepressants, antiepileptics, opioids, lidocaine patches was not accepted the day before and the day of the visit
* Pregnancy
* Treatment with NO releasing drugs, anti-cytokine therapy
* Diabetes mellitus type I, malignancy, increased pulmonary hypertension, cardiac ischemic disease, decreased glomerular filtration rate\<30 ml/min, decreased liver function, Glu-6-PDH deficiency
18 Years
75 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Uppsala University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Adriana Miclescu
MD, PhD, DEAA
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Adriana Miclescu
Role: PRINCIPAL_INVESTIGATOR
Uppsala University Hospital
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
NO8
Identifier Type: -
Identifier Source: org_study_id